argenx NV ADR (ARGX)vsRigel Pharmaceuticals Inc (RIGL)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
RIGL
Rigel Pharmaceuticals Inc
$26.29
+0.61%
HEALTHCARE · Cap: $489.54M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 1340% more annual revenue ($4.24B vs $294.28M). RIGL leads profitability with a 124.7% profit margin vs 30.5%. RIGL trades at a lower P/E of 1.4x. RIGL earns a higher WallStSmart Score of 79/100 (B+).
ARGX
Buy63
out of 100
Grade: C+
RIGL
Strong Buy79
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+96.2%
Fair Value
$911.66
Current Price
$26.29
$885.37 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 125 of every $100 in revenue as profit
Strong operational efficiency at 33.2%
Revenue surging 21.2% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
Smaller company, higher risk/reward
ROE of 1.9% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : RIGL
The strongest argument for RIGL centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 124.7% and operating margin at 33.2%. Revenue growth of 21.2% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : RIGL
The primary concerns for RIGL are Market Cap, Return on Equity.
Key Dynamics to Monitor
RIGL carries more volatility with a beta of 1.17 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RIGL scores higher overall (79/100 vs 63/100), backed by strong 124.7% margins and 21.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Rigel Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases. The company is headquartered in South San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?